Source: Reuters (via feed)
Danaher Corporation agreed to acquire pulse oximeter maker Masimo Corporation for $9.9 billion, including debt. The deal aims to strengthen Danaher’s diagnostics portfolio. Masimo is known for its pulse oximetry technology, which measures oxygen saturation in patients.
This acquisition comes as Danaher seeks to expand its footprint in healthcare technology. The company operates in various sectors, including life sciences and diagnostics, and is targeting growth through strategic acquisitions. Meanwhile, Masimo will become part of a larger organization focused on medical diagnostics.
The transaction is expected to close after the completion of regulatory reviews and customary closing conditions. Both companies will continue to operate in their respective markets until the deal finalizes. In addition, the agreement highlights consolidation trends in the healthcare diagnostics sector as firms seek to broaden product offerings.
Danaher will pay a mix of cash and stock to Masimo shareholders. This deal adds to recent healthcare mergers aimed at expanding capabilities and innovation in medical technologies.
The acquisition reflects ongoing consolidation in healthcare diagnostics, impacting competitive positioning and market share among medical device makers.
